EUVIMEDEUVIMED entdecken
Crossref

New Treatment Modalities in Hemophilia

Kaan Kavaklı

Trends in Pediatrics · 2022

DOI: 10.4274/tp.2022.03521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Pediatrics, 2022. Verfasst von Kaan Kavaklı. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder. Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy. Gold standart treatment is regularly prophylactic FVIII/FIX infusions. However, life-long and frequent intra-venous infusions become medical burden for patients and families. New agents as enhanced half-life (EHL) factor concentrates and non-factor therapies which are able to be used subcutaneously are very hopeful. In this review, EHL factor concentrates, FVIII mimetic agents and re-balancing therapies will be discussed. Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.

Zitieren

APA

Kavaklı, K. (2022). New Treatment Modalities in Hemophilia. Trends in Pediatrics. https://doi.org/10.4274/tp.2022.03521

Vancouver

Kavaklı K. New Treatment Modalities in Hemophilia. Trends in Pediatrics. 2022. doi:10.4274/tp.2022.03521

BibTeX
@article{Kavakl2022,
  author = {Kavaklı, Kaan},
  title = {New Treatment Modalities in Hemophilia},
  journal = {Trends in Pediatrics},
  year = {2022},
  doi = {10.4274/tp.2022.03521}
}
Kostenlos starten →